Skip to content
metaboliq

Semaglutide in India: weekly pens, daily tablets, and what each is approved for

Semaglutide is a long-acting copy of the gut hormone GLP-1. In India it comes as weekly pens (Ozempic, Wegovy and, since March 2026, generic brands) and as a daily tablet (Rybelsus). It is prescription-only, and a doctor decides which, if any, fits you.

Brands
Ozempic, Wegovy and Rybelsus (Novo Nordisk); Poviztra (Emcure); generic brands since March 2026.
Forms
A weekly pen under the skin, or a daily tablet.
Approved in India for
Depends on the product: type 2 diabetes, or chronic weight management at 2.4 mg.
Who decides
A doctor, after your history and blood tests.

How semaglutide works

Semaglutide copies GLP-1, a hormone the gut releases after a meal, and lasts about a week in the body. It slows how fast the stomach empties, increases fullness, quietens appetite and helps the pancreas release insulin when blood sugar rises.

Sources: [1]

Weekly pens and the daily tablet

The weekly pens are Ozempic, approved for type 2 diabetes, and Wegovy at 2.4 mg, the strength approved in India for chronic weight management. Emcure's Poviztra is a licensed version of Wegovy.

Rybelsus is semaglutide taken by mouth once a day. Its approved use is type 2 diabetes. It is taken on an empty stomach with a small sip of water, at least 30 minutes before food or anything else, because food stops it being absorbed.

Sources: [2], [1], [5], [6], [3]

The generic brands

The Indian patent expired in March 2026, and several companies launched their own semaglutide on 20 and 21 March. Reported prices at launch ran from about Rs 750 a week to about Rs 4,200 a month, depending on brand and strength.

The molecule is the same. What differs is the company, the pen and the strengths on offer, and each product is held to its own approved use.

Sources: [7], [8], [9], [13]

What the trials found

In STEP 1, adults on 2.4 mg weekly reduced body weight by an average of 14.9% over 68 weeks, against 2.4% on placebo. In SURMOUNT-5, tirzepatide reduced body weight further than semaglutide over the same period.

Sources: [10], [11]

Who decides, and how it is started

It is prescription-only in India, and a doctor decides whether it fits you after reading your history, your blood tests and anything else you take.

It is started at a low strength and stepped up every four weeks or so, because stepping up slowly is what keeps the stomach side effects manageable.

Sold outside an authorised pharmacy, a pen can be fake, wrongly stored or the wrong strength; the regulator has asked states to keep these products to authorised channels and their approved uses.

Sources: [13]

Why muscle matters

Body weight falls as fat and as lean tissue together. In the STEP 1 body-composition substudy, roughly 40% of the total lost was lean mass.

Muscle is what keeps blood sugar handled well, keeps you strong as you age and keeps your daily energy use up. So the plan around any treatment protects it: protein at every meal, strength training two or three times a week, and body composition measured rather than the scale alone.

Sources: [14]

What happens when it is stopped

These work while they are taken. One year after semaglutide was stopped in the STEP 1 extension, people had regained about two-thirds of what they had lost; in SURMOUNT-4, people switched from tirzepatide to placebo regained about 14% of body weight.

That is why the habits built alongside treatment, and a plan for maintenance, matter as much as the treatment itself.

Sources: [15], [16]

Side effects

Common, and usually easing with time

  • Nausea, most often in the first weeks and after each step up.
  • Diarrhoea or constipation.
  • Vomiting, indigestion, burping and bloating.
  • Feeling full early, and less appetite.
  • Tiredness, and headache.

Serious, and rare

  • Pancreatitis: severe, lasting pain in the upper abdomen that may spread to the back, with or without vomiting.
  • Gallbladder problems, including gallstones, which are more likely when body weight falls quickly.
  • Dehydration from vomiting or diarrhoea, which can strain the kidneys.
  • Low blood sugar, mainly when it is combined with insulin or a sulfonylurea.
  • Allergic reactions, rare but serious.
  • A history of medullary thyroid cancer or MEN 2 in you or your family is a reason it is not used.
  • NAION, a sudden painless loss of vision in one eye, listed as a very rare side effect of semaglutide.

Stop and get medical help at once for severe abdominal pain, repeated vomiting, signs of an allergic reaction, or sudden changes in vision. Tell the doctor about pregnancy plans first: these are not used in pregnancy.

Questions people ask

Is semaglutide the same as Ozempic?

Ozempic is one brand of semaglutide. Wegovy, Rybelsus, Poviztra and the generic brands are others, at different strengths and for different approved uses.

Do semaglutide tablets work as well as the pens?

They are a different product, absorbed only when taken exactly as the label says, on an empty stomach. Their approved use differs too. A doctor compares them for you.

Is semaglutide safe for Indians?

The East Asian trial STEP 6 and the first Indian cohort study found results in the same direction as elsewhere. Safety is individual: a doctor reads your history and blood tests first.

Every source, in full

  1. [1] Wegovy: EPAR and product information

    European Medicines Agency, 2025. The full label for semaglutide 2.4 mg: approved for chronic weight management, with its warnings and side effects.

    Read the source
  2. [2] Ozempic: EPAR and product information

    European Medicines Agency, 2025. The full label: Ozempic is approved for adults with type 2 diabetes, with its warnings and the side effects seen in trials.

    Read the source
  3. [3] Rybelsus: EPAR and product information

    European Medicines Agency, 2025. The label for semaglutide taken by mouth: approved for type 2 diabetes, taken on an empty stomach with a little water.

    Read the source
  4. [4] Semaglutide 2.4 mg once a week in adults with overweight or obesity in East Asia (STEP 6)

    The Lancet Diabetes & Endocrinology, 2022. In adults in East Asia, semaglutide 2.4 mg weekly reduced body weight by an average of 13.2% over 68 weeks, in line with results elsewhere.

    Read the source
  5. [5] Novo Nordisk's Wegovy gets CDSCO nod for fatty liver disease indication

    Business Standard, 2026. Wegovy, launched in India in June 2025 for chronic weight management, received a further approval from the national regulator in July 2026.

    Read the source
  6. [6] Emcure launches Poviztra

    Emcure press release, 2025. Emcure launched Poviztra, semaglutide 2.4 mg under licence from Novo Nordisk, with a starting monthly price of about Rs 8,790.

    Read the source
  7. [7] Generic semaglutide launches in India, including by Dr Reddy's, Zydus, Alkem, Sun Pharma and Glenmark

    Pearce IP, 2026. Several Indian companies launched semaglutide on 20 and 21 March 2026, once the patent expired; Zydus put its Semaglyn at about Rs 2,200 a month.

    Read the source
  8. [8] Sun Pharma, Dr Reddy's, Glenmark launch generic semaglutide in India

    Business Standard, 2026. Reports the March 2026 launches, with Sun Pharma's Noveltreat at about Rs 750 to Rs 2,000 a week depending on strength.

    Read the source
  9. [9] Generic semaglutide launch in India, 2026

    Omnicuris, 2026. Reports Dr Reddy's Obeda at about Rs 4,200 a month.

    Read the source
  10. [10] Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)

    New England Journal of Medicine, 2021. Adults on semaglutide 2.4 mg weekly, with diet and activity, reduced body weight by an average of 14.9% over 68 weeks, against 2.4% on placebo.

    Read the source
  11. [11] Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)

    New England Journal of Medicine, 2025. Head to head over 72 weeks, average body-weight reduction was 20.2% with tirzepatide and 13.7% with semaglutide 2.4 mg.

    Read the source
  12. [12] First Indian cohort study on tirzepatide and semaglutide, reported

    ThePrint, 2026. In 150 people treated at one Indian hospital, the median reduction in body weight at about six months was 8.2%, and somewhat larger with tirzepatide than with semaglutide.

    Read the source
  13. [13] DCGI letter to states on the sale and promotion of GLP-1 receptor agonists, 27 March 2026

    Central Drugs Standard Control Organisation, via Medical Dialogues, 2026. Directs states to ensure these products are sold only through authorised channels, strictly in line with their approved indications and labelling.

    Read the source
  14. [14] Body composition changes with semaglutide in the STEP 1 body-composition substudy, reviewed

    Postgraduate Medicine, 2022. In the STEP 1 body-composition substudy, roughly 40% of the total body weight lost was lean mass rather than fat.

    Read the source
  15. [15] Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension

    Diabetes, Obesity and Metabolism, 2022. One year after semaglutide was stopped, participants had regained about two-thirds of the body weight they had lost.

    Read the source
  16. [16] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4)

    JAMA, 2024. After 36 weeks on tirzepatide, people switched to placebo regained about 14% of body weight by week 88; people who continued went on to a further 5.5% reduction.

    Read the source

Talk to a doctor about your own results.

A registered doctor reads your blood report and your history, and decides with you what comes next.